Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

The Clavien-Dindo Classification of Surgical Complications

Pierre A. Clavien, Jeffrey Barkun, Michelle Oliveira et al. · Annals of Surgery · 2009 · 11.3K citations

Medicine, Surgery, Clinical Classification Systems +13

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Nizar M. Tannir, Osvaldo Arén Frontera et al. · New England Journal of Medicine · 2018 · 4.6K citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · New England Journal of Medicine · 2019 · 3.4K citations · Full text

Medicine, Oncology, Pharmacology +9

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text

Medicine, Oncology, Pharmacotherapy +12